Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tregalizumab plus methotrexate for active rheumatoid arthritis after inadequate response to methotrexate
2013-000114-38Phase 2Terminated
- Sponsor
- Biotest AG
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tregalizumab in rheumatoid arthritis (RA) (4 arms), sponsored by Biotest AG. Primary endpoint: ACR20 response at Week 12. Started May 2013; status: terminated.
02
Drugs
tregalizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-000114-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000114-38.